Effects of low-density lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from human hepatoma cell lines

J. Yang, Y. Gong, D. P. Sontag, I. Corbin, G. Y. Minuk

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid with anti-cancer properties. Recently, DHA packaged within low-density lipoprotein (LDL) nanoparticles (LDL–DHA) was demonstrated to be effective in a murine model of hepatocellular carcinoma (HCC). Cancer stem cells (CSCs) are a subpopulation of tumor cells that are resistant to most cancer therapies and thereby, contribute to tumor recurrences. To determine whether LDL–DHA is effective against CSCs derived from human HCC cell lines and tumor bearing rats. Epithelial cellular adhesion molecule positive and CD133 negative (EpCAM+CD133) CSCs were isolated from HuH-7 and HepG2 human HCC lines and exposed to varying concentrations (1–60 µM) of LDL–DHA nanoparticles for 0–72 h. HCC tumor bearing rats were treated with 2 mg/kg LDL–DHA nanoparticles for 3 days. Regardless of the cell line employed, LDL–DHA nanoparticles achieved 70–100% killing of EpCAM+CD133 CSCs at a concentration of 40 µM after 48 h of exposure while DHA and LDL alone had minimal or no cytotoxic effects. Similar results were obtained with LDL–DHA nanoparticle treatment of EpCAMCD133 adult cancer cells (ACCs). In keeping with these findings were similar levels of low density lipoprotein receptor expression and LDL–DHA nanoparticle induced lipid peroxidation activity and reactive oxygen species in the CSC and ACC populations. However, differences in sensitivity to LDL–DHA treatment were observed in vivo experiments where LDL–DHA nanoparticle treated tumors had a higher percent of surviving CSCs relative to ACCs. Further research on LDL–DHA nanoparticle therapy for human HCC is warranted.

Original languageEnglish (US)
JournalMolecular Biology Reports
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Neoplastic Stem Cells
Docosahexaenoic Acids
LDL Lipoproteins
Nanoparticles
Hepatocellular Carcinoma
Cell Line
Neoplasms
LDL Receptors
Omega-3 Fatty Acids
Tumor Cell Line
Unsaturated Fatty Acids
Lipid Peroxidation
Reactive Oxygen Species
Recurrence

Keywords

  • Cancer stem cells
  • Docosahexaenoic acid
  • Hepatocellular carcinoma
  • HepG2
  • HuH-7
  • Low density lipoproteins
  • Nanoparticles

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Effects of low-density lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from human hepatoma cell lines. / Yang, J.; Gong, Y.; Sontag, D. P.; Corbin, I.; Minuk, G. Y.

In: Molecular Biology Reports, 01.01.2018.

Research output: Contribution to journalArticle

@article{ec26431451ae4550817525f14eebf621,
title = "Effects of low-density lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from human hepatoma cell lines",
abstract = "Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid with anti-cancer properties. Recently, DHA packaged within low-density lipoprotein (LDL) nanoparticles (LDL–DHA) was demonstrated to be effective in a murine model of hepatocellular carcinoma (HCC). Cancer stem cells (CSCs) are a subpopulation of tumor cells that are resistant to most cancer therapies and thereby, contribute to tumor recurrences. To determine whether LDL–DHA is effective against CSCs derived from human HCC cell lines and tumor bearing rats. Epithelial cellular adhesion molecule positive and CD133 negative (EpCAM+CD133−) CSCs were isolated from HuH-7 and HepG2 human HCC lines and exposed to varying concentrations (1–60 µM) of LDL–DHA nanoparticles for 0–72 h. HCC tumor bearing rats were treated with 2 mg/kg LDL–DHA nanoparticles for 3 days. Regardless of the cell line employed, LDL–DHA nanoparticles achieved 70–100{\%} killing of EpCAM+CD133− CSCs at a concentration of 40 µM after 48 h of exposure while DHA and LDL alone had minimal or no cytotoxic effects. Similar results were obtained with LDL–DHA nanoparticle treatment of EpCAM−CD133− adult cancer cells (ACCs). In keeping with these findings were similar levels of low density lipoprotein receptor expression and LDL–DHA nanoparticle induced lipid peroxidation activity and reactive oxygen species in the CSC and ACC populations. However, differences in sensitivity to LDL–DHA treatment were observed in vivo experiments where LDL–DHA nanoparticle treated tumors had a higher percent of surviving CSCs relative to ACCs. Further research on LDL–DHA nanoparticle therapy for human HCC is warranted.",
keywords = "Cancer stem cells, Docosahexaenoic acid, Hepatocellular carcinoma, HepG2, HuH-7, Low density lipoproteins, Nanoparticles",
author = "J. Yang and Y. Gong and Sontag, {D. P.} and I. Corbin and Minuk, {G. Y.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s11033-018-4252-2",
language = "English (US)",
journal = "Molecular Biology Reports",
issn = "0301-4851",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Effects of low-density lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from human hepatoma cell lines

AU - Yang, J.

AU - Gong, Y.

AU - Sontag, D. P.

AU - Corbin, I.

AU - Minuk, G. Y.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid with anti-cancer properties. Recently, DHA packaged within low-density lipoprotein (LDL) nanoparticles (LDL–DHA) was demonstrated to be effective in a murine model of hepatocellular carcinoma (HCC). Cancer stem cells (CSCs) are a subpopulation of tumor cells that are resistant to most cancer therapies and thereby, contribute to tumor recurrences. To determine whether LDL–DHA is effective against CSCs derived from human HCC cell lines and tumor bearing rats. Epithelial cellular adhesion molecule positive and CD133 negative (EpCAM+CD133−) CSCs were isolated from HuH-7 and HepG2 human HCC lines and exposed to varying concentrations (1–60 µM) of LDL–DHA nanoparticles for 0–72 h. HCC tumor bearing rats were treated with 2 mg/kg LDL–DHA nanoparticles for 3 days. Regardless of the cell line employed, LDL–DHA nanoparticles achieved 70–100% killing of EpCAM+CD133− CSCs at a concentration of 40 µM after 48 h of exposure while DHA and LDL alone had minimal or no cytotoxic effects. Similar results were obtained with LDL–DHA nanoparticle treatment of EpCAM−CD133− adult cancer cells (ACCs). In keeping with these findings were similar levels of low density lipoprotein receptor expression and LDL–DHA nanoparticle induced lipid peroxidation activity and reactive oxygen species in the CSC and ACC populations. However, differences in sensitivity to LDL–DHA treatment were observed in vivo experiments where LDL–DHA nanoparticle treated tumors had a higher percent of surviving CSCs relative to ACCs. Further research on LDL–DHA nanoparticle therapy for human HCC is warranted.

AB - Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid with anti-cancer properties. Recently, DHA packaged within low-density lipoprotein (LDL) nanoparticles (LDL–DHA) was demonstrated to be effective in a murine model of hepatocellular carcinoma (HCC). Cancer stem cells (CSCs) are a subpopulation of tumor cells that are resistant to most cancer therapies and thereby, contribute to tumor recurrences. To determine whether LDL–DHA is effective against CSCs derived from human HCC cell lines and tumor bearing rats. Epithelial cellular adhesion molecule positive and CD133 negative (EpCAM+CD133−) CSCs were isolated from HuH-7 and HepG2 human HCC lines and exposed to varying concentrations (1–60 µM) of LDL–DHA nanoparticles for 0–72 h. HCC tumor bearing rats were treated with 2 mg/kg LDL–DHA nanoparticles for 3 days. Regardless of the cell line employed, LDL–DHA nanoparticles achieved 70–100% killing of EpCAM+CD133− CSCs at a concentration of 40 µM after 48 h of exposure while DHA and LDL alone had minimal or no cytotoxic effects. Similar results were obtained with LDL–DHA nanoparticle treatment of EpCAM−CD133− adult cancer cells (ACCs). In keeping with these findings were similar levels of low density lipoprotein receptor expression and LDL–DHA nanoparticle induced lipid peroxidation activity and reactive oxygen species in the CSC and ACC populations. However, differences in sensitivity to LDL–DHA treatment were observed in vivo experiments where LDL–DHA nanoparticle treated tumors had a higher percent of surviving CSCs relative to ACCs. Further research on LDL–DHA nanoparticle therapy for human HCC is warranted.

KW - Cancer stem cells

KW - Docosahexaenoic acid

KW - Hepatocellular carcinoma

KW - HepG2

KW - HuH-7

KW - Low density lipoproteins

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85051186801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051186801&partnerID=8YFLogxK

U2 - 10.1007/s11033-018-4252-2

DO - 10.1007/s11033-018-4252-2

M3 - Article

C2 - 30069818

AN - SCOPUS:85051186801

JO - Molecular Biology Reports

JF - Molecular Biology Reports

SN - 0301-4851

ER -